ATE386941T1 - Methode zur feststellung der therapeutischen aktivität eines mbp fragments - Google Patents

Methode zur feststellung der therapeutischen aktivität eines mbp fragments

Info

Publication number
ATE386941T1
ATE386941T1 AT03022727T AT03022727T ATE386941T1 AT E386941 T1 ATE386941 T1 AT E386941T1 AT 03022727 T AT03022727 T AT 03022727T AT 03022727 T AT03022727 T AT 03022727T AT E386941 T1 ATE386941 T1 AT E386941T1
Authority
AT
Austria
Prior art keywords
mbp
residues
levels
amino acid
synthetic peptides
Prior art date
Application number
AT03022727T
Other languages
English (en)
Inventor
Kenneth Warren
Ingrid Catz
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Application granted granted Critical
Publication of ATE386941T1 publication Critical patent/ATE386941T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT03022727T 1997-04-04 1998-04-03 Methode zur feststellung der therapeutischen aktivität eines mbp fragments ATE386941T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2201841A CA2201841C (en) 1997-04-04 1997-04-04 Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients

Publications (1)

Publication Number Publication Date
ATE386941T1 true ATE386941T1 (de) 2008-03-15

Family

ID=4160340

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98914725T ATE400582T1 (de) 1997-04-04 1998-04-03 Myelin basic protein peptidfragmente, deren pharmazeutische zusammensetzungen und verwendung gegen multiple sklerose
AT03022727T ATE386941T1 (de) 1997-04-04 1998-04-03 Methode zur feststellung der therapeutischen aktivität eines mbp fragments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98914725T ATE400582T1 (de) 1997-04-04 1998-04-03 Myelin basic protein peptidfragmente, deren pharmazeutische zusammensetzungen und verwendung gegen multiple sklerose

Country Status (20)

Country Link
EP (2) EP1394178B1 (de)
JP (1) JP4173557B2 (de)
AT (2) ATE400582T1 (de)
AU (1) AU751303B2 (de)
CA (2) CA2494338C (de)
CY (2) CY1107445T1 (de)
CZ (1) CZ299535B6 (de)
DE (2) DE69839163T2 (de)
DK (2) DK0970121T3 (de)
ES (2) ES2307317T3 (de)
HU (1) HU226768B1 (de)
NO (1) NO325018B1 (de)
NZ (1) NZ338091A (de)
PL (1) PL191965B1 (de)
PT (2) PT1394178E (de)
RO (1) RO119303B1 (de)
RU (1) RU2198893C2 (de)
SK (1) SK285815B6 (de)
UA (1) UA60331C2 (de)
WO (1) WO1998045327A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541106A (zh) 2001-06-11 2004-10-27 转新疗法公司 用维生素b12和治疗剂联合治疗病毒性、增殖性和炎性疾病的方法
RU2261713C1 (ru) * 2004-04-27 2005-10-10 Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" Способ лечения тяжелой формы острого оптического неврита у пациентов с рассеянным склерозом
JP5709876B2 (ja) 2009-10-12 2015-04-30 ライフバイオ ラボラトリーズ エルエルシーLIFEBio LABORATORIES LLC 多発性硬化症治療用組成物
RU2646817C1 (ru) * 2016-12-27 2018-03-07 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид из состава тяжелой цепи иммуноглобулина человека, пригодный для лечения рассеянного склероза

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021611C1 (ru) * 1991-04-19 1994-10-15 Михайленко Анатолий Андреевич Способ диагностики рассеянного склероза
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
DE69331501T2 (de) * 1992-04-09 2002-08-29 Autoimmune, Inc. Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
CZ122697A3 (en) * 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
SK132999A3 (en) 2000-06-12
JP2001518885A (ja) 2001-10-16
NZ338091A (en) 2001-10-26
EP0970121B1 (de) 2008-07-09
PL191965B1 (pl) 2006-07-31
CZ299535B6 (cs) 2008-08-27
ES2307317T3 (es) 2008-11-16
DE69839163D1 (de) 2008-04-03
EP1394178B1 (de) 2008-02-20
DK1394178T3 (da) 2008-05-26
HK1063805A1 (en) 2005-01-14
NO994806L (no) 1999-12-06
SK285815B6 (sk) 2007-08-02
PT970121E (pt) 2008-09-22
RU2198893C2 (ru) 2003-02-20
ATE400582T1 (de) 2008-07-15
PL336085A1 (en) 2000-06-05
EP1394178A1 (de) 2004-03-03
ES2299657T3 (es) 2008-06-01
DK0970121T3 (da) 2008-10-20
RO119303B1 (ro) 2004-07-30
CY1107445T1 (el) 2012-12-19
CZ9903464A3 (cs) 2000-11-15
UA60331C2 (uk) 2003-10-15
CY1108239T1 (el) 2014-02-12
HUP0000812A3 (en) 2000-10-30
HUP0000812A2 (hu) 2000-09-28
EP0970121A1 (de) 2000-01-12
NO325018B1 (no) 2008-01-14
NO994806D0 (no) 1999-10-01
CA2494338A1 (en) 1998-10-04
DE69839163T2 (de) 2009-02-12
CA2201841C (en) 2010-01-26
AU751303B2 (en) 2002-08-15
PT1394178E (pt) 2008-04-15
JP4173557B2 (ja) 2008-10-29
HU226768B1 (en) 2009-09-28
DE69839694D1 (de) 2008-08-21
CA2201841A1 (en) 1998-10-04
AU6913098A (en) 1998-10-30
WO1998045327A1 (en) 1998-10-15
CA2494338C (en) 2007-07-17

Similar Documents

Publication Publication Date Title
NZ293910A (en) Peptides useful in immunoregulation of antibodies to human myelin basic protein, pharmaceutical compositions and method of treatment
DK0662827T4 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
WO1993023434A3 (en) Bpi-immunoglobulin fusion proteins
AU2750092A (en) Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
DE69839163D1 (de) Methode zur Feststellung der therapeutischen Aktivität eines MBP Fragments
NZ335835A (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
EP0723016A3 (de) Leukocyten-aktivierender Faktor
BR0012740A (pt) Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1394178

Country of ref document: EP

REN Ceased due to non-payment of the annual fee